Melatonin in cancer treatment

[1]  A. Seely,et al.  Melatonin as Adjuvant Cancer Care With and Without Chemotherapy , 2012, Integrative cancer therapies.

[2]  C. Duan,et al.  The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: a meta-analysis of randomized controlled trials , 2012, Cancer Chemotherapy and Pharmacology.

[3]  R. Reiter,et al.  Clinical uses of melatonin: evaluation of human trials. , 2010, Current medicinal chemistry.

[4]  Nihal Ahmad,et al.  Sirtuins, melatonin and circadian rhythms: building a bridge between aging and cancer , 2010, Journal of pineal research.

[5]  J. Jacobson,et al.  Use of antioxidant supplements during breast cancer treatment: a comprehensive review , 2009, Breast Cancer Research and Treatment.

[6]  D. Skene,et al.  Physiology and pharmacology of melatonin in relation to biological rhythms , 2009, Pharmacological reports : PR.

[7]  R. Reiter,et al.  Role of melatonin in the epigenetic regulation of breast cancer , 2009, Breast Cancer Research and Treatment.

[8]  M. Melan,et al.  Melatonin and breast cancer: cellular mechanisms, clinical studies and future perspectives , 2009, Expert Reviews in Molecular Medicine.

[9]  J. Boutin,et al.  Melatonin receptors, heterodimerization, signal transduction and binding sites: what's new? , 2008, British journal of pharmacology.

[10]  Douglas G. Altman,et al.  Statistical Methods for Examining Heterogeneity and Combining Results from Several Studies in Meta‐Analysis , 2008 .

[11]  D. Cardinali,et al.  Melatonergic Drugs in Clinical Practice , 2008, Arzneimittel-Forschung (Drug Research).

[12]  Robert A Newman,et al.  Impact of antioxidant supplementation on chemotherapeutic efficacy: a systematic review of the evidence from randomized controlled trials. , 2007, Cancer treatment reviews.

[13]  M. Sydes,et al.  Practical methods for incorporating summary time-to-event data into meta-analysis , 2007, Trials.

[14]  S. V. Anisimov,et al.  Melatonin as antioxidant, geroprotector and anticarcinogen. , 2006, Biochimica et biophysica acta.

[15]  Nicholas M. Radio,et al.  Melatonin enhances alkaline phosphatase activity in differentiating human adult mesenchymal stem cells grown in osteogenic medium via MT2 melatonin receptors and the MEK/ERK (1/2) signaling cascade , 2006, Journal of pineal research.

[16]  G. Guyatt,et al.  Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta‐analysis , 2005, Journal of pineal research.

[17]  Simon G. Thompson,et al.  Meta‐Analysis of Clinical Trials , 2005 .

[18]  Antoine Martin,et al.  Preventive and curative effect of melatonin on mammary carcinogenesis induced by dimethylbenz[a]anthracene in the female Sprague–Dawley rat , 2005, Breast Cancer Research.

[19]  R. Reiter,et al.  Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism , 2005, The Prostate.

[20]  C. Martínez-Campa,et al.  Melatonin, an Endogenous-specific Inhibitor of Estrogen Receptor α via Calmodulin* , 2004, Journal of Biological Chemistry.

[21]  Josep M. Guerrero,et al.  Melatonin inhibits telomerase activity in the MCF‐7 tumor cell line both in vivo and in vitro , 2003, Journal of pineal research.

[22]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[23]  R. Reiter,et al.  Melatonin Reduces Oxidant Damage and Promotes Mitochondrial Respiration , 2002, Annals of the New York Academy of Sciences.

[24]  R. Reiter,et al.  Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. , 2002, Current topics in medicinal chemistry.

[25]  S. Cos,et al.  Direct antiproliferative effects of melatonin on two metastatic cell sublines of mouse melanoma (B16BL6 and PG19) , 2001, Melanoma research.

[26]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[27]  M. Parmar,et al.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. , 1998, Statistics in medicine.

[28]  M. D. Mediavilla,et al.  Effects of melatonin on mammary gland lesions in transgenic mice overexpressing N‐rasproto‐oncogene , 1997, Journal of pineal research.

[29]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[30]  A. Lerner,et al.  ISOLATION OF MELATONIN, THE PINEAL GLAND FACTOR THAT LIGHTENS MELANOCYTES1 , 1958 .

[31]  L. Fuentes-Broto,et al.  Melatonin: a multitasking molecule. , 2010, Progress in brain research.

[32]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.